ESCRS Showcase

Article

A brief overview of some of the products that will be showcased during the ESCRS Congress

Surgery platform

The OS4 will be premiered at the Oertli booth, B09, during the congress exhibition. "We have redefined the concept of the operating platform for cataract, glaucoma and retina surgery," said Thomas Bosshard, head of marketing and sales. "The OS4 includes everything we are good at: cutting-edge technology, perfect design, irresistible simplicity, the highest degree of safety and Swiss quality."

Booth number: B09

Website: http://www.oertli-instruments.com/

Microscopes with integrated 3D technology

The partnership between the two companies combines optical and digital microscopy into one platform and is aimed at driving precise patient outcomes, enhancing surgeon ergonomics and facilitating OR staff communication.

Dr Heinrich Dreyer, vice president of Leica Microsystems, Medical Division, said, "The partnership leverages Leica Microsystems' 'open architecture' and world-class optical, ergonomic microscopes and TrueVision's cutting edge visualization platform and suite of software applications. This integration creates a seamless, upgradeable platform that will help surgeons gain a more realistic perception of anatomical structures as a result of the depth perceived in 3D."

Booth number: A17

Website: http://www.leica-microsystems.com/

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.